A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine

Sirukumab 100 mg subcutaneous (SC) injection, at Weeks 0, 2, and every 2 weeks through Week 52.

Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.

Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.